StockNow
Calendar
Log in
U.S. Markets

Roivant (ROIV) and Immunovant (IMVT) announces topline results from proof-of-concept study of IMVT-1402 in cutaneous Lupus Erythematosus

StockNow breaking-news AI analysis

IMVT-1402 missed the primary endpoint in a cutaneous lupus erythematosus study despite positive IgG-linked trends, while maintaining favorable safety and keeping other clinical timelines on track.

News detail

Immunovant’s proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12. Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies All other clinical development timelines remain on track

2 stocks
ROIVRoivant Sciences Ltd. Common Shares$37.10Current priceIMVTImmunovant, Inc. Common Stock$34.61Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Diplomatic sources suggest that "Yesterday's talks between the US and Iran did not achieve the minimum required to resume negotiations", Hayom reports

Geopolitics

Unconfirmed reports of explosions in the Strait of Hormuz; some suggestion that four missiles have been launched towards Hormuz - UNVERIFIED

U.S. Markets

Bank of America (BAC) Co-President Demare says continued strength in macroeconomic backdrop; Q3 will not be as robust in markets as Q2 was

BAC